Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our lab has an interest in studying how cellular Ubiquitylation and ISGylation influence cancer inflammation with the final aim of translating these findings into valid therapeutic targets. To study these pathways we use state-of-the-art MS-based omics techniques such as proteomics and lipidomics in combination with immunology and cellular biology functional assays.

Current team members

RESEARCH OVERVIEW

Current research involves the study of the roles of a class of druggable enzymes called deubiquitylating enzymes (DUBs) in cancer inflammation using advanced proteomics, lipidomics, and immunology techniques as main tools.  

For instance, we have recently discovered that cancer cells lacking the DUB USP18, a negative regulator of the interferon pathway, are more antigenic and radiosensitive. At a molecular level, USP18-deficient cells accumulate innate immune ligands such as dsRNA, enhance the antigen presentation machinery, and hence they can activate more efficiently cytotoxic T cells, resulting in enhanced T cell killing and immunotherapy responses. 

Pinto-Fernandez, A., Salio, M., Partridge, T. et al. Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity. Br J Cancer 124, 817–830 (2021). (DOI: 10.1038/s41416-020-01167-y).

Other relevant references:

https://doi.org/10.3389/fgene.2016.00133

https://doi.org/10.3390/biom12020300

DOI: 10.1038/nature24451

https://doi.org/10.7554/eLife.71596

DOI: 10.26508/lsa.202000768

https://doi.org/10.1083/jcb.202004211

 

TRAINING OPPORTUNITIES

We are experts in the study of the ubiquitin system in disease-relevant models using advanced ubiquitomics (GG-petidomics), activity-based protein profiling (ABPP), proteomics, lipidomics, chemical biology, cellular biology, and immunology techniques. These methodologies and matching data analysis approaches can be applied and learnt in our laboratory. Importantly, as part of the COI-NDM environment, we have access to cutting-edge technology assuring the highest available standards in terms of data quality. 

Finally, our laboratory has been always very interested in the translational aspect of our research and as a consequence, we have been involved in a number of collaborations with industry partners (including Pfizer, Incyte, Xcellomics, ONO, FORMA therapeutics, and others). This provides an excellent opportunity to learn the complementary research dynamics happening in pharmaceutical companies.

References on methodology:

https://doi.org/10.3390/biom10101453

https://doi.org/10.3390/ijms23063263

https://doi.org/10.3389/fchem.2021.640105

https://doi.org/10.3389/fchem.2019.00592

Our team & Collaborators

Related research themes